Needham & Company LLC set a $33.00 price target on Collegium Pharmaceutical (NASDAQ:COLL) in a research note issued to investors on Friday, TipRanks reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other research firms have also commented on COLL. BidaskClub raised shares of Collegium Pharmaceutical from a sell rating to a hold rating in a report on Tuesday, August 13th. Zacks Investment Research lowered shares of Collegium Pharmaceutical from a buy rating to a hold rating in a report on Friday, October 11th. William Blair reaffirmed a buy rating on shares of Collegium Pharmaceutical in a report on Tuesday, September 17th. Cantor Fitzgerald reaffirmed an overweight rating and set a $24.00 target price (down previously from $35.00) on shares of Collegium Pharmaceutical in a report on Thursday, August 8th. Finally, ValuEngine raised shares of Collegium Pharmaceutical from a sell rating to a hold rating in a report on Thursday, August 1st. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $24.00.

Shares of COLL stock traded down $0.52 on Friday, hitting $11.56. 263,851 shares of the company’s stock traded hands, compared to its average volume of 315,521. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.20 and a current ratio of 1.25. Collegium Pharmaceutical has a one year low of $10.01 and a one year high of $19.83. The company’s fifty day simple moving average is $11.54 and its 200 day simple moving average is $12.33. The stock has a market capitalization of $404.32 million, a price-to-earnings ratio of -9.71 and a beta of 0.52.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.05. Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. The company had revenue of $75.04 million for the quarter, compared to analyst estimates of $75.77 million. During the same quarter last year, the firm earned ($0.40) EPS. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Collegium Pharmaceutical will post -0.51 earnings per share for the current fiscal year.

In other Collegium Pharmaceutical news, Director David Hirsch sold 22,106 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $11.65, for a total transaction of $257,534.90. Following the completion of the sale, the director now owns 64,223 shares of the company’s stock, valued at approximately $748,197.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 8.08% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC purchased a new stake in Collegium Pharmaceutical during the 3rd quarter valued at $98,000. Meeder Asset Management Inc. boosted its position in Collegium Pharmaceutical by 1,299.5% during the 3rd quarter. Meeder Asset Management Inc. now owns 8,495 shares of the specialty pharmaceutical company’s stock valued at $97,000 after buying an additional 7,888 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in Collegium Pharmaceutical during the 3rd quarter valued at $116,000. Atria Investments LLC boosted its position in Collegium Pharmaceutical by 35.0% during the 2nd quarter. Atria Investments LLC now owns 22,842 shares of the specialty pharmaceutical company’s stock valued at $260,000 after buying an additional 5,928 shares during the period. Finally, Royal Bank of Canada boosted its position in Collegium Pharmaceutical by 33.7% during the 2nd quarter. Royal Bank of Canada now owns 17,275 shares of the specialty pharmaceutical company’s stock valued at $227,000 after buying an additional 4,350 shares during the period. 92.08% of the stock is owned by institutional investors and hedge funds.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Recommended Story: Compound Interest and Why It Matters When Investing

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.